相伴的
医学
药物警戒
倾向得分匹配
内科学
心力衰竭
优势比
心脏病学
不良事件报告系统
置信区间
回顾性队列研究
不利影响
药理学
CYP2C19型
低风险
危险系数
逻辑回归
作者
Daqiu Chen,Yanqing Wu,Zhanxiong Xie,Qiu Wx,Xiaomai Huang,Shanghua Xu,Shunxiang Luo
标识
DOI:10.3389/fphar.2026.1846852
摘要
Background Mavacamten, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (HOCM), carries a risk of excessive negative inotropy. Because mavacamten is metabolized primarily by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, concomitant CYP inhibitors may increase mavacamten exposure. We evaluated real-world heart failure-related reporting patterns associated with concomitant CYP inhibitor exposure in mavacamten-treated HOCM reports. Methods We conducted a retrospective pharmacovigilance study using the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from the second quarter (Q2) of 2022 to the fourth quarter (Q4) of 2025. Mavacamten-treated HOCM reports were screened for concomitant exposure to ten prespecified CYP2C19 and/or CYP3A4 inhibitors. Heart failure-related signals were defined using seven Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms. Severe outcomes were extracted from FAERS outcome fields; hospitalization was defined as initial or prolonged hospitalization, and death as a reported fatal outcome. Analyses included the reporting odds ratio (ROR), additive signal amplification index (S), time-to-onset modeling, multivariable logistic regression, and 1:4 propensity score matching (PSM). Results Among 3,570 mavacamten-treated HOCM reports, 347 involved concomitant CYP inhibitor exposure. Combination therapy showed an elevated heart failure-related reporting signal (ROR = 25.08; 95% confidence interval [CI], 18.63–33.76) and potential reporting signal amplification (S = 2.71). Agent-specific reporting signals were heterogeneous across prespecified inhibitors. Weibull modeling showed an early-failure pattern (β = 0.88; median onset, 80 days). Compared with mavacamten monotherapy, combination therapy had higher reported proportions of hospitalization (28.5% vs. 13.5%) and death (5.5% vs. 2.3%). Concomitant CYP inhibitor exposure showed higher heart failure-related reporting odds after multivariable adjustment (adjusted odds ratio [aOR], 2.52; 95% CI, 1.10–5.62) and in the PSM sensitivity cohort (aOR, 1.99; P < 0.001). Conclusion Concomitant use of mavacamten with selected CYP inhibitors was associated with increased heart failure-related reporting in FAERS. Careful medication reconciliation and clinical vigilance are warranted, while recognizing that spontaneous reporting data cannot establish causality.
科研通智能强力驱动
Strongly Powered by AbleSci AI